FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
GlobalData on MSN5d
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
Monthly Prescribing Reference4d
Hympavzi Approved for Treatment of Hemophilia A or B
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
Pfizer drug for hemophilia approved by FDA
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...
The Financial Express5d
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.
Daily5d
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
Zacks.com on MSN1d
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
Here's a recap of the week’s most important stories.
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Pharmabiz5d
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...